[go: up one dir, main page]

CL2012001348A1 - Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. - Google Patents

Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.

Info

Publication number
CL2012001348A1
CL2012001348A1 CL2012001348A CL2012001348A CL2012001348A1 CL 2012001348 A1 CL2012001348 A1 CL 2012001348A1 CL 2012001348 A CL2012001348 A CL 2012001348A CL 2012001348 A CL2012001348 A CL 2012001348A CL 2012001348 A1 CL2012001348 A1 CL 2012001348A1
Authority
CL
Chile
Prior art keywords
disease
compound
treatment
pharmaceutical composition
hemitartrate
Prior art date
Application number
CL2012001348A
Other languages
English (en)
Inventor
Jeffrey Skell
John Marshall
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Ji Kochling
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2012001348A1 publication Critical patent/CL2012001348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Molecular Biology (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Forma amorfa y cristalina de la sal de hemitartrato de un compuesto de fórmula (I), inhibidor de glucosilceramida sintasa; composición farmacéutica que lo comprende; método de tratamiento para la enfermedad de Gaucher y para la enfermedad de Fabry.
CL2012001348A 2009-11-27 2012-05-24 Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry. CL2012001348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
CL2012001348A1 true CL2012001348A1 (es) 2012-08-24

Family

ID=43431870

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001348A CL2012001348A1 (es) 2009-11-27 2012-05-24 Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
CL2016002589A CL2016002589A1 (es) 2009-11-27 2016-10-12 Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016002589A CL2016002589A1 (es) 2009-11-27 2016-10-12 Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).

Country Status (41)

Country Link
US (6) US11458119B2 (es)
EP (5) EP2504332B2 (es)
JP (6) JP2013512252A (es)
KR (6) KR20250005503A (es)
CN (5) CN102712629B (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA2781676C (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK2796457T3 (es)
DO (2) DOP2012000141A (es)
EA (3) EA023923B1 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2754398T3 (es)
GT (1) GT201200161A (es)
HK (2) HK1203485A1 (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE029371T2 (es)
IL (4) IL310635A (es)
LT (2) LT3133070T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (2) MX358345B (es)
MY (2) MY192644A (es)
NI (1) NI201200096A (es)
NZ (3) NZ600155A (es)
PE (2) PE20121337A1 (es)
PH (2) PH12012501048A1 (es)
PL (4) PL2504332T5 (es)
PT (4) PT3599237T (es)
RS (3) RS54978B1 (es)
SG (2) SG10201800136QA (es)
SI (3) SI2796457T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI586663B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
RS54978B1 (sr) 2009-11-27 2016-11-30 Genzyme Corp Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
WO2013181530A1 (en) 2012-06-01 2013-12-05 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
EP2968479B1 (en) 2013-03-14 2019-07-17 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
CN105745206B (zh) * 2013-09-20 2019-08-13 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
EP3164128A4 (en) * 2014-07-03 2018-02-28 Dr. Reddy's Laboratories Ltd. Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EA201891170A1 (ru) 2015-11-18 2018-11-30 Джензим Корпорейшн Биомаркер поликистозной болезни почек и варианты его применения
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
CA3067044A1 (en) * 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
CN116139130A (zh) * 2017-12-15 2023-05-23 建新公司 治疗戈谢病的方法
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
CN112512558A (zh) * 2018-05-27 2021-03-16 比奥阿赛斯技术有限公司 戈谢病的治疗
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
EP0720852B1 (en) 1993-08-13 2000-11-22 Seikagaku Corporation Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
WO1995021175A1 (en) 1994-02-02 1995-08-10 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
AU698833B2 (en) 1994-06-10 1998-11-12 Seikagaku Corporation 2-acylaminopropanol compound and medical composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
ATE358473T1 (de) 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
DE04010651T1 (de) 2000-04-24 2005-09-01 Teva Pharmaceutical Industries Ltd. Mikronisiertes Zolpidem-Hemitartrat
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
KR20030067755A (ko) 2001-01-18 2003-08-14 메르크 파텐트 게엠베하 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
WO2003008399A1 (en) 2001-07-16 2003-01-30 Genzyme Corporation Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
EP2479290B1 (en) 2004-09-30 2020-08-19 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2006040649A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
JP2009510163A (ja) * 2005-10-03 2009-03-12 マリンクロッド・インコーポレイテッド ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
WO2008121826A2 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
EP2594565B1 (en) * 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307181A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
RS54978B1 (sr) 2009-11-27 2016-11-30 Genzyme Corp Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
BR112012012617B8 (pt) 2009-11-27 2021-05-25 Adverio Pharma Gmbh processo para a produção de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
MX2013014887A (es) 2011-06-21 2014-02-17 Novartis Ag Polimorfos de 1- ({4-metil-5- [2- (2 ,2 ,2-trifluoro-1,1-dimetil-e til) piridin-4-il] - tiazol-2-il}-amida de 2-amida del acido (s) -pirrolidin-1,2-dicarboxilico.
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
BR112012012947A2 (pt) 2017-03-01
NZ600155A (en) 2014-10-31
EP2504332B2 (en) 2021-03-17
DOP2012000141A (es) 2012-09-30
PL3133070T3 (pl) 2020-01-31
PL2796457T3 (pl) 2017-04-28
PL2504332T3 (pl) 2014-10-31
TW201737910A (zh) 2017-11-01
PT3133070T (pt) 2019-11-11
KR20250005503A (ko) 2025-01-09
DK2796457T3 (en) 2016-08-29
MY192644A (en) 2022-08-29
RS53503B1 (en) 2015-02-27
JP2016138124A (ja) 2016-08-04
PL2504332T5 (pl) 2021-08-23
CA3075788C (en) 2021-12-21
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
EP3599237A1 (en) 2020-01-29
CN112521366A (zh) 2021-03-19
KR20150125734A (ko) 2015-11-09
NI201200096A (es) 2012-10-30
KR20120115972A (ko) 2012-10-19
ECSP18063798A (es) 2020-02-28
WO2011066352A1 (en) 2011-06-03
LT2796457T (lt) 2016-09-12
CA2781676C (en) 2020-05-05
ES2493940T5 (es) 2021-11-23
JP2023116764A (ja) 2023-08-22
TWI656873B (zh) 2019-04-21
HUE029371T2 (en) 2017-02-28
AU2017265180A1 (en) 2017-12-14
ES2754398T3 (es) 2020-04-17
BR112012012947B1 (pt) 2021-04-06
EP2796457B1 (en) 2016-05-18
JP6370264B2 (ja) 2018-08-08
AU2016202591B2 (en) 2017-11-30
TN2012000237A1 (en) 2013-12-12
EA201890254A2 (ru) 2018-10-31
SMT201600273B (it) 2016-08-31
PL3599237T3 (pl) 2021-09-27
SG10201407881WA (en) 2015-01-29
PE20171255A1 (es) 2017-08-28
JP2015212291A (ja) 2015-11-26
CL2016002589A1 (es) 2017-05-19
US20160166542A1 (en) 2016-06-16
SG10201800136QA (en) 2018-02-27
RS53503B2 (sr) 2021-07-30
HRP20161038T1 (hr) 2016-10-21
EP2504332B1 (en) 2014-06-04
ES2493940T3 (es) 2014-09-12
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
HRP20191647T1 (hr) 2019-12-13
PT2796457T (pt) 2016-07-14
EA201592195A1 (ru) 2016-04-29
IL219892A0 (en) 2012-07-31
TWI586663B (zh) 2017-06-11
DK2504332T3 (da) 2014-08-25
ECSP12011926A (es) 2012-07-31
AU2010324810A1 (en) 2012-06-07
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
BR112012012947B8 (pt) 2021-05-25
JP6452635B2 (ja) 2019-01-16
US20210369672A1 (en) 2021-12-02
SI2504332T2 (sl) 2021-08-31
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
SI2796457T1 (sl) 2016-10-28
MX2012006083A (es) 2012-06-19
JP2013512252A (ja) 2013-04-11
GT201200161A (es) 2014-01-27
CN105753846B (zh) 2019-11-15
LT3133070T (lt) 2019-11-11
US10888547B2 (en) 2021-01-12
SI3133070T1 (sl) 2019-11-29
PT2504332E (pt) 2014-09-02
EA023923B1 (ru) 2016-07-29
ES2586947T3 (es) 2016-10-19
SI2504332T1 (sl) 2014-09-30
RS54978B1 (sr) 2016-11-30
AU2016202591A1 (en) 2016-05-19
EP3133070A1 (en) 2017-02-22
CA3075788A1 (en) 2011-06-03
CN105777707B (zh) 2020-10-13
ES2875382T3 (es) 2021-11-10
EP3599237B1 (en) 2021-03-24
TW201639562A (zh) 2016-11-16
PH12012501048A1 (en) 2013-02-04
JP2019001809A (ja) 2019-01-10
HK1203485A1 (zh) 2015-10-30
PH12015502514B1 (en) 2022-07-29
EA029990B1 (ru) 2018-06-29
HUE045784T2 (hu) 2020-01-28
MX381242B (es) 2025-03-12
IL260299A (en) 2018-08-30
DOP2016000250A (es) 2017-02-15
MY160542A (en) 2017-03-15
AR079152A1 (es) 2011-12-28
KR20200013105A (ko) 2020-02-05
PH12015502514A1 (en) 2016-08-15
CY1115880T1 (el) 2017-01-25
RS59543B1 (sr) 2019-12-31
IL283935A (en) 2021-07-29
CN102712629A (zh) 2012-10-03
KR20220162824A (ko) 2022-12-08
DK3133070T3 (da) 2019-11-11
EP3133070B1 (en) 2019-08-14
CA2781676A1 (en) 2011-06-03
CN112521367A (zh) 2021-03-19
JP2020189873A (ja) 2020-11-26
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
US20230172903A1 (en) 2023-06-08
US11458119B2 (en) 2022-10-04
US20130137743A1 (en) 2013-05-30
CN102712629B (zh) 2016-10-12
KR20180049255A (ko) 2018-05-10
AU2017265180B2 (en) 2019-08-01
NZ715108A (en) 2017-06-30
CY1117996T1 (el) 2017-05-17
DK2504332T4 (da) 2021-06-07
IL310635A (en) 2024-04-01
CY1122698T1 (el) 2021-03-12
EP2504332A1 (en) 2012-10-03
CR20120277A (es) 2012-09-05
EA201270646A1 (ru) 2013-01-30
EA201890254A3 (ru) 2019-02-28
ME02477B (me) 2017-02-20
PT3599237T (pt) 2021-04-28
HK1172031A1 (en) 2013-04-12
EP2796457A1 (en) 2014-10-29
MA33838B1 (fr) 2012-12-03
TW201130822A (en) 2011-09-16
UA113491C2 (xx) 2017-02-10
CN112521367B (zh) 2024-01-02
WO2011066352A8 (en) 2011-08-11
HRP20140780T1 (en) 2014-11-07
US20160120842A1 (en) 2016-05-05
EP3896069A1 (en) 2021-10-20
JP7150528B2 (ja) 2022-10-11
AR121612A2 (es) 2022-06-22
CA3140959A1 (en) 2011-06-03
HRP20140780T4 (hr) 2021-08-06

Similar Documents

Publication Publication Date Title
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
DK2516433T3 (da) Substituerede n-(1h-indazol-4-yl)imidazo[1,2-a]pyridin-3-carboxamidforbindelser som cfms-inhibitorer
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CU20110207A7 (es) Aril piridinas como inhibidoras de sintasa de aldosterona
UY32062A (es) Inhibidores de beta-secretasa
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
UY32432A (es) Compuestos de pirimidina fusionada como inhibidores de akt
ECSP11011307A (es) Comprimidos para terapia de combinacion
PH12013502434A1 (en) Substituted pyridopyrazines as novel syk inhibitors
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
PH12014500499A1 (en) Triazolopyridine compounds as pde10a inhibitors
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
CL2013001221A1 (es) Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CL2011000292A1 (es) Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
ECSP13012459A (es) Valsartan altamente cristalino
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
EA201000611A1 (ru) 4,4-дизамещенные пиперидины